Short Courses and Special Courses
SC33 - Ovarian Carcinoma: An Update on Histotype Diagnosis, Primary Site Assignment, and Staging
Thursday, March 22, 2018 - 8:00 am - 11:30 am
This Short Course session includes up to a half-hour break.
3 CME and 3 SAMs
C. Blake Gilks, MD, University of British Columbia, Vancouver, BC
M. Köbel, MD, University of Calgary, Calgary, AB
Naveena Singh, MD, FRCPath, Barts Health NHS Trust, London, UK
This is a practically-oriented course on ovarian epithelial malignancies, and is designed for general surgical pathologists and pathology residents. There have been important recent developments in the pathology of ovarian carcinomas, the most common ovarian malignancy, that impact on routine surgical pathology practice, and these developments are the focus of this course. Accurate diagnosis of ovarian carcinoma Histotype is important for treatment and for assessment of genetic risk, and there are immunomarkers available that can serve as aids in Histotype diagnosis. There are also recent advances in our understanding of site of origin of these carcinomas that impact on assignment of primary site and stage in our diagnostic pathology reports. Finally, neoadjuvant chemotherapy is increasingly being used, and criteria have been developed (and adopted by the International Collaboration on Cancer Reporting) that allow reproducible and clinically relevant assessment of treatment response. This course will consist of an introduction on clinical aspects of ovarian carcinoma followed by a series of case presentations, with virtual slides, illustrating important diagnostic points and pitfalls in ovarian carcinoma Histotype differential diagnosis, selection and interpretation of immunostains, assessing response to chemotherapy, and primary site assignment/staging. There will be a brief presentation on quality assurance for immunostains of relevance to ovarian carcinoma Histotype diagnosis (e.g. WT1, Napsin A, p53).
- Present criteria that allow for accurate and reproducible diagnosis of high-grade serous, low-grade serous, mucinous, endometrioid, clear cell, and mixed ovarian carcinoma.
- Provide an overview of the clinical importance of accurate diagnosis of ovarian carcinoma Histotype
- Describe how immunostains can be used in selected cases to improve the accuracy of Histotype diagnosis, and how optimal staining quality can be achieved with these immunostains in your laboratory
- Offer practical guidelines for primary site assignment, staging and assessment of response to neoadjuvant chemotherapy in the most common Histotype, high-grade serous carcinoma.
Upon completion of this educational activity, the learner will be able to:
- Accurately diagnosis ovarian carcinoma Histotypes, applying immunostains in selected difficult cases as an aid in Histotype diagnosis.
- Consistently assign primary site and stage, and assess response to neoadjuvant chemotherapy in cases of high-grade serous carcinoma.
- Describe how immunostains can be used in selected cases to improve the accuracy of Histotype diagnosis.
Continuing Medical Education and Maintenance of Certification
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 3 SAM credit hours.
Return to 2018 Annual Meeting Short Course Page